Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U3RV
|
|||
| Former ID |
DIB004607
|
|||
| Drug Name |
Motexafin lutetium
|
|||
| Synonyms |
Lutetium texaphyrin; Lu-Tex; Motexafin lutetium < USAN; Optrin (Pharmacyclics); PCI-0123; Antrin (Pharmacyclics, US, US); Lutrin (National Cancer Institute (US), US; Pharmacyclics, , , JP); (PB-7-11-233'2'4)-Bis(acetato-O)[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Artery stenosis [ICD-11: BD52; ICD-10: I51.89] | Phase 3 | [1] | |
| Company |
Pharmacyclics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C52H74LuN5O15
|
|||
| Canonical SMILES |
CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].O.[Lu+3]
|
|||
| InChI |
1S/C48H66N5O10.2C2H4O2.Lu.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);;1H2/q-1;;;+3;/p-2
|
|||
| InChIKey |
WIQKYZYFTAEWBF-UHFFFAOYSA-L
|
|||
| CAS Number |
CAS 156436-90-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostate specific antigen (KLK3) | Target Info | Modulator | [1] |
| KEGG Pathway | Pathways in cancer | |||
| Prostate cancer | ||||
| Pathway Interaction Database | Coregulation of Androgen receptor activity | |||
| Regulation of Androgen receptor activity | ||||
| FOXA1 transcription factor network | ||||
| Reactome | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| WikiPathways | Prostate Cancer | |||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.